Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06445166 · ClinicalTrials.gov registry record · Phase 2
Propranolol for the Treatment of Kaposi Sarcoma in Adults
A Phase 2 study of Kaposi Sarcoma, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06445166 is a Phase 2 study of Kaposi Sarcoma that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 25 participants, below the 101-participant average among 13 other Kaposi Sarcoma trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06445166, a Phase 2 study of Kaposi Sarcoma, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Kaposi sarcoma (KS) lesions are initiated by endothelial cells infected with KS herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). Lesion progression is driven by abnormal angiogenesis, chronic inflammation, and uncontrolled cell proliferation. KS remains one of the most commonly diagnosed cancers in many African countries where economic constraints prevent successful treatment in most patients. Treatment outcomes in developed countries are also often unsatisfactory in HIV positive patients despite good virological and immunological responses to antiretroviral therapy. Therefore, identification of new oral, safe treatment options for treatment of KS remains a research priority. Given the known anti-angiogenic properties and based on the treatment response with other benign vascular lesions such as infantile hemangioma, propranolol is a good candidate for the treatment of KS. The hypothesis of this study is that treating patients with Kaposi sarcoma with propranolol will result in an overall response rate (complete response rate plus partial response rate) of at least 45%, and that propranolol will be safe and well tolerated in this patient population.
Conditions Studied
Interventions
- DRUG Propranolol Hydrochloride
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-08-20 |
| Est. Completion | 2028-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06445166
The ClinicalTrials.gov registry entry for NCT06445166 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 13 other Kaposi Sarcoma trials with a reported enrollment target (75% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kaposi Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Propranolol Hydrochloride is the first listed.
NCT06445166 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT06445166 about?
NCT06445166 is a clinical study titled "Propranolol for the Treatment of Kaposi Sarcoma in Adults". Kaposi sarcoma (KS) lesions are initiated by endothelial cells infected with KS herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). Lesion progression is driven by abnormal angiogenesis, chronic inflammation, and uncontrolled cell proliferation. KS remains one of the most commonly diagnos...
What is the current status of trial NCT06445166?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-08-20. Estimated completion is 2028-08-01.
What conditions does trial NCT06445166 study?
This clinical trial studies the following conditions: Kaposi Sarcoma.
What interventions are being tested in trial NCT06445166?
The interventions under investigation include: Propranolol Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT06445166?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06445166 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kaposi Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Ixazomib for Kaposi Sarcoma
RECRUITING · Phase 2
-
Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
RECRUITING · Phase 2
-
A Study of sEphB4-HSA in Kaposi Sarcoma
RECRUITING · Phase 2
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
RECRUITING · Phase 1
-
PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.